HomeBUSINESS
BUSINESS

Takeda Launches Entyvio in Japan for Ulcerative Colitis
(Nov.8.2018)

Takeda Pharmaceutical’s ulcerative colitis (UC) treatment Entyvio for IV Infusion 300 mg (vedolizumab) hit the Japanese market on November 7 following its NHI price listing in August, the company announced on the same day ...
(LOG IN FOR FULL STORY)